Literature DB >> 16469994

Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1.

Riccardo Caccialanza1, Giovanni Palladini, Catherine Klersy, Hellas Cena, Christina Vagia, Barbara Cameletti, Paola Russo, Francesca Lavatelli, Giampaolo Merlini.   

Abstract

BACKGROUND: Maintenance of a good nutritional status is associated with prolonged survival in many chronic diseases. To date, the nutritional status of outpatients with immunoglobulin light-chain (AL) amyloidosis has not been evaluated.
OBJECTIVE: The aims of this study were to obtain information regarding the nutritional status of AL amyloidosis outpatients and to investigate its prognostic role.
DESIGN: One hundred six consecutive patients with histologically confirmed AL amyloidosis were enrolled. Anthropometric, biochemical, and clinical variables were measured. The Kaplan-Meier method was used to calculate survival. A Cox proportional hazard model was constructed to evaluate the prognostic effect of the nutritional variables.
RESULTS: Unintentional weight loss (median: 11.3%; range: 2.6-34% of usual nonedematous body weight) was documented in 58 subjects (54.7%). Body mass index (BMI; in kg/m2) was <22 in 25 subjects (23.6%). Serum prealbumin was <200 mg/L (lower reference limit) in 26 patients (24.5%). A multivariate analysis showed that the percentage weight loss was significantly greater in patients with than in those without cardiac involvement (P = 0.03), and it also differed significantly by New York Heart Association class (P = 0.02) and Eastern Cooperative Oncology Group performance status (P = 0.001). Cardiac involvement (P = 0.008), hematologic response to therapy (P = 0.013), BMI (P = 0.001) and serum prealbumin (P = 0.001) were independent predictors of survival.
CONCLUSIONS: Malnutrition is a prominent clinical feature of patients with AL amyloidosis. Appropriate nutritional evaluation that comprises the easily measurable nutritional variables associated with survival should be an integral part of the clinical assessment of AL amyloidosis outpatients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16469994     DOI: 10.1093/ajcn/83.2.350

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  9 in total

1.  Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

Authors:  Giovanni Palladini; Paolo Milani; Andrea Foli; Laura Obici; Francesca Lavatelli; Mario Nuvolone; Riccardo Caccialanza; Stefano Perlini; Giampaolo Merlini
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

Review 2.  Dietary advice with or without oral nutritional supplements for disease-related malnutrition in adults.

Authors:  Christine Baldwin; Marian Ae de van der Schueren; Hinke M Kruizenga; Christine Elizabeth Weekes
Journal:  Cochrane Database Syst Rev       Date:  2021-12-21

3.  Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Authors:  G Palladini; P Milani; A Foli; M Vidus Rosin; M Basset; F Lavatelli; M Nuvolone; L Obici; S Perlini; G Merlini
Journal:  Leukemia       Date:  2014-07-25       Impact factor: 11.528

4.  A prospective study of nutritional status in immunoglobulin light chain amyloidosis.

Authors:  Prayman T Sattianayagam; Thirusha Lane; Zoe Fox; Aviva Petrie; Simon D J Gibbs; Jennifer H Pinney; Signe S Risom; Dorota M Rowczenio; Ashutosh D Wechalekar; Helen J Lachmann; Janet A Gilbertson; Philip N Hawkins; Julian D Gillmore
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

Review 5.  Systemic amyloidosis and the gastrointestinal tract.

Authors:  Prayman T Sattianayagam; Philip N Hawkins; Julian D Gillmore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-01       Impact factor: 46.802

Review 6.  Novel Therapies in Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Kidney Int Rep       Date:  2017-11-28

Review 7.  Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-03-01       Impact factor: 2.576

8.  Prognostic Value of Pretreatment Serum Transthyretin Level in Patients with Gastrointestinal Cancers.

Authors:  Hongliang Luo; Jun Huang; Zhengming Zhu; Peiqian Zhu
Journal:  Dis Markers       Date:  2019-06-03       Impact factor: 3.434

Review 9.  Dental-craniofacial manifestation and treatment of rare diseases.

Authors:  En Luo; Hanghang Liu; Qiucheng Zhao; Bing Shi; Qianming Chen
Journal:  Int J Oral Sci       Date:  2019-02-20       Impact factor: 6.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.